- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05176470
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
A Phase IB Study to Assess the Safety and Efficacy of Neoadjuvant Administration of Autologous Tumor Infiltrating Lymphocytes (LN144/Lifileucel) and Pembrolizumab for Treatment of Patients With Locally Advanced (Stage IIIB-D)/Metastatic (Stage IV) Melanoma
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the feasibility of the neoadjuvant administration of Pembrolizumab and LN-144 (Lifileucel) isolated from tumor-involved metastatic lymph node(s) in 3 stage IIIB-D melanoma patients. (Part 1) II. To evaluate the safety profile and surgical tolerability of MK-3475 (pembrolizumab) and LN-144 (Lifileucel) in 12 patients, as measured by the incidence of grade >= 3 treatment-emergent adverse events (TEAEs). (Part 2)
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of Pembrolizumab and LN-144(Lifileucel) in 12 patients by determining the overall objective response rate (ORR), using the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) and immune-related RECIST (irRECIST) criteria, as assessed by the investigator. (Part 2 only) II. To further evaluate the efficacy of Pembrolizumab and LN-144 (Lifileucel) in 12 patients using the 24-month relapse-free survival rate (RFS), using RECIST 1.1 and irRECIST, as assessed by the investigator. (Part 2 only)
EXPLORATORY OBJECTIVES:
I. To determine rates of major pathologic response (MPR) for high-risk stage IIIB-D melanoma patients treated with neoadjuvant administration of MK-3475 (pembrolizumab) and LN-144 (Lifileucel).
II. To determine the association between the proportion of PD-1+CD4+ or CD8+ tumor infiltrating lymphocytes (TILs) isolated from tumor involved lymph node(s) via flow cytometry, and probability of MPR, ORR, and RFS.
III. To determine the association between neoantigen specificity and probability of MPR, ORR, and RFS.
IV. To determine the correlation between tumor mutation burden (TMB) and MPR, ORR, and RFS.
V. To determine the correlation between intratumoral IFN-gamma and T-effector gene signatures and probability of MPR, ORR, and RFS.
VI. To evaluate the correlation between serum cytokines (IL-8, IL-6), and probability of MPR, ORR, and RFS.
VII. To evaluate the success rates of growing TILs from lymph node metastases, and the potential predictive factors (i.e., patient's age, CD8/CD4 ratios, inhibitory receptor expressions).
VIII. To correlate the doses of TILs infused to patients and the probability of MPR, ORR, and RFS.
IX. To perform additional translational studies utilizing the unstained slides or FFPE (paraffin blocks) on the resected melanoma tumor specimen post LN-144 (Lifileucel) neoadjuvant therapy.
OUTLINE:
Patients receive pembrolizumab intravenously (IV) on day -14, cyclophosphamide IV once daily (QD) on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and lifileucel IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.
MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be 18 to 75 years of age
- Must have a confirmed diagnosis of Stage IIIB-D locally advanced or Stage IV melanoma (American Joint Committee on Cancer [AJCC] 8th edition) with measurable disease in the lymph node(s) documented by computed tomography (CT) or ultrasound imaging (>= 15 mm short axis) or by physical exam. Patients must also have measurable primary site of disease, including cutaneous and/or intransit metastases by imRECIST (>= 20 mm chest x-ray [CXR], >= 10 mm CT, or >= 10 mm by exam)
- No prior therapy is allowed
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of >= 3 months in the opinion of the investigator
- Patients must have at least one easily accessible measurable tumor-involved lymph node(s) documented by CT or ultrasound imaging for TIL harvest
- Patients must be amenable to have ultrasound examination of measurable lymph node(s) and have pathologic confirmation of melanoma metastases in the lymph node (fine needle aspiration [FNA] acceptable) in the 28 days preceding the first administration of the treatment
- Patients with and without BRAF V600E/K mutations are included.
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
- Patients with a history of herpes simplex virus (HSV) infection must have been treated. Patients with a history of Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection must be asymptomatic and have low viral loads
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. To be eligible for this trial, patients should be class 2B or better
Women must not be pregnant or breast-feeding due to potential harm to an unborn fetus and possible risk of adverse events in nursing infants with the anti-PD-1 regimen(s) being used.
- All females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy.
- A female of childbearing potential is defined as any woman, regardless of sexual orientation, or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding consecutive months)
- Women of childbearing potential and sexually active males must not conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of study registration and continuing until at least 5 months after the last dose of anti-PD-1 treatment for female patients and for at least 7 months after the last dose of anti-PD-1 treatment for male patients who are sexually active with a woman of childbearing potential (WOCBP).
- Patients must have adequate organ and marrow function as defined below at study enrollment and prior to surgical resection. (these labs must be obtained ≤ 4 weeks prior to protocol registration and ≤1 week prior to surgery):
- Hemoglobin >= 10 g/dL
- Neutrophils >= 1500/ul
- Leukocytes >= 3000/ul
- Lymphocytes >= 700/ul
- Blood platelet >= 100,000/ul
- Serum creatinine =< 1.5 x upper limit of normal or creatinine clearance (CrCl) >= 40 mL/min (if using the Cockcroft-Gault formula)
- Serum bilirubin =< 2.0 mg/dL
- Total bilirubin =< 1.5 x upper limit of normal (except for patients with Gilbert syndrome, who can have total bilirubin < 3 mg/dL)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal
- Lactate dehydrogenase (LDH) =< 1.5 x upper limit of normal
- Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), and agree to abide by the study restrictions and return to the site for the required assessments, including the RFS Follow-up Period
Exclusion Criteria:
- Ocular/uveal melanoma
- Chemotherapy or radiotherapy within 4 weeks before baseline (6 weeks for nitroso-urea and mitomycin C)
- Contraindication for the use of vasopressor agents
- Patients with HIV active infection or seropositivity are excluded. Patients with active Hep B or Hep C based on serology and viral load are excluded. Patients with active CMV or EBV based on serology and viral load are excluded.
- History or current manifestation of severe progressive heart disease (congestive heart failure with LVEF < 50% by echocardiogram or MUGA scan, coronary artery disease, uncontrolled arterial hypertension, uncontrolled arrhythmia, or myocardial infarction in the past 6 months.
- Patients with active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids.
- Patients should be excluded if they had prior treatment with an anti- PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
Patients who have a history of hypersensitivity to immune checkpoint therapy drug(s) or any component or excipient of LN-144 or other study drugs:
- Nivolumab, pembrolizumab, or related products
- Any monoclonal antibody
- NMA-LD preconditioning regimen (cyclophosphamide, mesna, and fludarabine)
- Proleukin, aldesleukin, IL-2
- Antibiotics (ABX) of the aminoglycoside group (i.e., streptomycin, gentamicin); except those who are skin-test negative for gentamicin hypersensitivity
- Any component of the LN-144 infusion product formulation including dimethyl sulfoxide (DMSO), human serum albumin (HSA), IL-2, and dextran-40
- History of chronic autoimmune disease (Addison's disease, multiple sclerosis, Graves' disease, rheumatoid arthritis, systemic lupus erythematosus, etc…) except patient with active vitiligo or a history of vitiligo. Patients with history of psoriasis is allowed
- History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea.
- Patients who have had another primary malignancy within the previous 3 years (except for those which do not require treatment or have been curatively treated >1 year ago, and in the judgment of the Investigator, does not pose a significant risk of recurrence including, but not limited to, non-melanoma skin cancer, DCIS, LCIS, prostate cancer Gleason score ≤6).
- Any serious, acute or chronic illness (i.e., active infection) needing antibiotics administration, coagulation's disorders, or any medical disorder requiring unauthorized concomitant treatment described in this study.
- Positive serology for HTLV1/HTLV2, or syphilis.
- Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
Patients who have obstructive or restrictive pulmonary disease and have a documented forced expiratory volume in 1 second (FEV1) of ≤ 60% of predicted normal:
- If a patient is not able to perform reliable spirometry due to abnormal upper airway anatomy (i.e., tracheostomy), a 6- minute walk test may be used to assess pulmonary function.
- Patients who are unable to walk a distance of at least 80% predicted for age and sex or demonstrates evidence of hypoxia at any point during the test (SpO2 < 90%) are excluded.
- Active infections, including COVID-19, within 30 days, unless deemed fully resolved/treated by the study PI.
- Participated in another clinical study with an investigational product within 21 days of the initiation of treatment.
- Adults under a legal protection regime (i.e., guardianship, trusteeship).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (pembrolizumab, lifileucel)
Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and lifileucel IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80. MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. |
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo surgery
Given by IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of neoadjuvant administration of MK-3475 and LN-144/Lifileucel in 3 stage IIIB-D melanoma patients (Phase 1)
Time Frame: Up to 2 years
|
Success rate of tumor infiltrating lymphocyte (TIL) expansion from all screened eligible patients who have had tumor-involved lymph node(s) removed; percentage of all eligible patients who have completed the screening and treated with LN-144/lifileucel.
|
Up to 2 years
|
Incidence of grade >= 3 treatment-emergent adverse events (both immune and non-immune related) (Phase 2)
Time Frame: Up to 2 years
|
The severity of AEs will be graded according to CTCAE version 5.0, and frequencies and percentages of patients with AEs will be tabulated by severity grade.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall objective response rate
Time Frame: Up to 2 years
|
Evaluated by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) and immune-related RECIST (irRECIST) criteria.
|
Up to 2 years
|
Relapse-free survival (RFS) rate
Time Frame: At 24 months
|
Kaplan-Meier method will be used to estimate the median time and the corresponding 95% CI.
|
At 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major pathologic response (MPR) rate
Time Frame: Up to 2 years
|
MPR will be summarized by number and percentage of patients with major pathologic response, as well as the corresponding 2-sided exact 95% confidence intervals (95% CI).
|
Up to 2 years
|
Immune correlates (as described above) with respect to response and 24-month relapse free survival, of the TIL/LN-144 + pembrolizumab neoadjuvant therapy
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Success rate of TIL growth from tumor-involved lymph node(s)
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Doses of the infused TIL with respect to response and 24-month relapse-free survival
Time Frame: Up to 2 years
|
Up to 2 years
|
|
Changes in the patients' health-related quality of life
Time Frame: Up to 2 years
|
Measured by a standardized questionnaire during and after the study protocol.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard C Wu, M.D. Ph.D., Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Skin Neoplasms
- Melanoma, Cutaneous Malignant
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Cyclophosphamide
- Pembrolizumab
- Fludarabine
Other Study ID Numbers
- OSU-21202
- NCI-2021-11063 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Melanoma
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)United States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Melanoma | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditionsUnited States
-
Qilu Hospital of Shandong UniversityNot yet recruitingLocally Advanced or Metastatic Acral Malignant MelanomaChina
-
Gregory DanielsImmunotherapy FoundationRecruitingMetastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck CancerUnited States
-
Array BioPharmaTerminatedLocally Advanced Metastatic BRAF Mutant MelanomaAustralia, Canada, Netherlands, United States
-
PfizerCompletedLocally Advanced or Metastatic NRAS Mutant MelanomaUnited States, Australia, Germany, Italy, Netherlands
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedAdvanced Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States
-
Karyopharm Therapeutics IncActive, not recruitingLocally Advanced Unresectable or Metastatic MelanomaUnited States
-
LetolabNot yet recruitingLocally Advanced or Metastatic CRC
Clinical Trials on Pembrolizumab
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States